Over the past decade, immune-engaging bispecific antibodies have transformed the treatment of blood cancers. However, the design principles that make these bispecific antibodies effective in hematologic malignancies have not translated successfully to solid tumors.

To achieve efficacy without dose-limiting toxicities, Rondo’s immune-engaging bispecific antibodies are designed to target solid tumors through precisely tuned immune-activating arms and tumor-localized activity. Our therapeutics aim to deliver durable responses while giving clinicians the flexibility to tailor dosing strategies and combination regimens to achieve the best outcomes for patients.

Our NGS-based antibody discovery platform enables the rapid generation of diverse binding arm libraries. A fixed light-chain format allows flexible pairing of immune effector and tumor-targeting arms, while our proprietary functional and developability screens identify molecules with the desired potency range and optimal clinical properties.